AB0878 Comparison of clinical features in patients with psoriatic arthritis and patients with spondyloarthritis with inflammatory bowel disease

Background Spondyloarthritis (SpA) is one of the representative comorbidity in patients with psoriasis (PsO) and inflammatory bowel disease (IBD) disease. However, the difference of clinical features between SpA due to PsO (PsA) and SpA due to IBD (IBD-SpA) are unclear. Objectives The purpose of this study is to compare the clinical features between patients with PsA and IBD-SpA. Methods Overall, 192 patients with PsO and 37 patients with IBD were included in this cross-sectional study. Clinical classification of PsA and IBD-SpA were performed according to the CASPAR1 criteria and ASAS criteria.2 Disease activity (DAS28-CRP), C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide antibody (ACPA), rheumatoid factor (RF), biologic disease modifying anti-rheumatic drugs (bDMARDs) use, and proportion of peripheral and axial disease were evaluated in patients with PsA and IBD-SpA. Results In this analysis, 74 patients were classified as PsA, 65 patients as PsO, 17 patients as IBD-SpA and 20 patients as IBD. The mean age was 56.0±14.7 years in PsA, 44.7±10.9 years in IBD-SpA (p=0.003). The mean BMI was 24.2±4.5 kg/m2 in PsA, 23.3±7.2 kg/m2 in IBD-SpA (p=0.18). DAS28-CRP was 3.26±1.26 in PsA, 4.02±1.5 in IBD-SpA (p=0.12). Axial SpA was observed in 4 (5.4%) in PsA, 5 (29.4%) in IBD-SpA (p=0.01). Biologics were used in 29 (39.2%) patients in PsA, 13 (76.5%) patients in IBD-SpA (p=0.007). Proportion of seropositive ratio was not significant in this two groups.Abstract AB0878 – Table 1 Characteristics in patients with PsO, PsA, IBD and IBD-SpA. PsA (n=74) PsO (n=65) IBD-SpA (n=17) IBD (n=20) P value* Age, years 56.0±14.7 60.2±14.0 44.7±10.9 45.0±12.8 0.003 Female, n (%) 36 (48.6) 29 (44.6) 8 (47.0) 16 (80.0) 1.0 Height, m 1.63±0.09 1.61±0.09 1.65±0.07 1.59±0.06 0.43 Body weight, kg 65.3±16.8 61.7±13.1 64.7±24.8 51.8±12.2 0.34 BMI, kg/m2 24.2±4.5 23.7±3.9 23.3±7.2 20.4±3.9 0.18 DAS28-CRP 3.26±1.26 1.91±0.9 4.02±1.5 2.53±0.8 0.12 CRP, mg/dl 1.32±3.3 0.32±0.6 1.0±1.1 0.78±2.4 0.12 MMP-3, ng/ml 99.9±95.3 92.1±59.0 0.90 ACPA positive, n (%) 6 (8.1) 0 (0) 0.59 RF positive, n (%) 7 (9.5) 1 (5.9) 1 *Mann-Whitney U-test and Fisher’s exact test were performed in comparison with PsA and IBD-SpA.Abstract AB0878 – Table 2 Prevalence of axial SpA and peripheral SpA in patients with PsA and IBD-SpA. PsA (n=74) IBD-SpA (n=17) P value Axial SpA, n (%) 4 (5.4) 5 (29.4) 0.01 Peripheral SpA, n (%) 70 (94.6) 12 (70.6) Conclusions The clinical features between patients with PsA and IBD-SpA were compared. The patient with IBD-SpA was younger than patient with PsA and the prevalence of axial disease was more frequent in IBD-SpA. References [1] Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73. [2] Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31. Acknowledgements We wish to thank Tomoko Nakatsuka for clinical assistant. Disclosure of Interest None declared